NCT02748967View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Healthy
Interventions
DRUG

ExPEC4V

Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.

DRUG

Placebo

Participant will receive single dose of Placebo on Day 1.

Trial Locations (1)

Unknown

Fukuoka

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT02748967 - A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants | Biotech Hunter | Biotech Hunter